Supernus Pharmaceuticals, Inc. (SUPN) Earnings Call Analysis
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Next earnings call: 2026-08-04
(Q2 2026)
— full calendar
Earnings Reports
-
Sopernis Pharmaceuticals (SUPN) Q1 2026: Growth Products Surge 56% as Adult ADHD Prescribers Overtake Pediatrics
May 06, 2026
-
Supernus (SUPN) Q4 2025: Growth Portfolio Drives 76% of Revenue as Supply Constraints Ease
February 26, 2026
-
Supernus (SUPN) Q3 2025: 78% Revenue Concentration in Four Growth Brands Signals Portfolio Shift
November 05, 2025
-
Supernus (SUPN) Q2 2025: Core Product Sales Jump 17% as Four Growth Drivers Reshape Portfolio
August 06, 2025
-
Supernus (SUPN) Q1 2025: Core Rx Revenue +26% as Calbry and GoCoveri Anchor Growth Amid Legacy Decline
July 07, 2025